Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: cisplatin

First Posted Date: 2005-11-29

Last Posted Date: 2009-06-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 10

Registration Number: NCT00259285

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Phase 1

Completed

Conditions: Malignant Pleural Mesotherioma

First Posted Date: 2005-11-10

Last Posted Date: 2007-11-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT00251550

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan

Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: carboplatin
Drug: pemetrexed

First Posted Date: 2005-10-06

Last Posted Date: 2019-06-04

Lead Sponsor: Northwestern University

Target Recruit Count: 51

Registration Number: NCT00234052

Locations: 🇺🇸
Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States

and more 2 locations

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2005-10-03

Last Posted Date: 2018-08-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 44

Registration Number: NCT00230542

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Phase 2 Trial of Bevacizumab in Combination With Pemetrexed

Phase 2

Completed

Conditions: Lung Cancer
Neoplasm Metastasis
Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Bevacizumab
Drug: Pemetrexed
Drug: Vitamin B12
Drug: Folate
Drug: Dexamethasone

First Posted Date: 2005-09-27

Last Posted Date: 2017-03-06

Lead Sponsor: Heather Wakelee

Target Recruit Count: 16

Registration Number: NCT00227019

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸
Cooper Cancer Institute, Voorhees, New Jersey, United States

and more 1 locations

Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Pemetrexed
Procedure: Surgery

First Posted Date: 2005-09-27

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 52

Registration Number: NCT00226577

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: Pemetrexed

First Posted Date: 2005-09-22

Last Posted Date: 2011-05-02

Lead Sponsor: Hoosier Cancer Research Network

Target Recruit Count: 43

Registration Number: NCT00216216

Locations: 🇺🇸
Siteman Cancer Center, St. Louis, Missouri, United States
🇺🇸
Community Regional Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Helen F. Graham Cancer Center, Newark, Delaware, United States

and more 13 locations

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cetuximab

First Posted Date: 2005-09-22

Last Posted Date: 2016-09-29

Lead Sponsor: Nasser Hanna, M.D.

Target Recruit Count: 36

Registration Number: NCT00216203

Locations: 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸
Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States

and more 8 locations

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: Pemetrexed
Drug: Bevacizumab

First Posted Date: 2005-09-22

Last Posted Date: 2016-02-15

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 42

Registration Number: NCT00222729

Locations: 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Pemetrexed
Dietary Supplement: Folic Acid
Dietary Supplement: Vitamin B12

First Posted Date: 2005-09-22

Last Posted Date: 2016-07-29

Lead Sponsor: Christopher Sweeney, MBBS

Target Recruit Count: 49

Registration Number: NCT00216099

Locations: 🇺🇸
Pennsylvania Oncology-Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy